Compounds > aspartic acid
Page last updated: 2024-08-17

aspartic acid and imatinib mesylate

aspartic acid has been researched along with imatinib mesylate in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dan, S; Kizaki, A; Mashima, T; Naito, M; Seimiya, H; Tsuruo, T1
Dougan, DR; Kraus, ML; Mol, CD; Sang, BC; Scheibe, DN; Schneider, TR; Skene, RJ; Snell, GP; Wilson, KP; Zou, H1
Brownlow, N; Dibb, NJ; Domin, J; Taylor, JR1
Berner, JM; Bruland, ØS; Holm, R; Joensuu, H; Kristian, A; Malinen, E; Revheim, ME; Seierstad, T1
Bardaweel, SK; El-Abadelah, MM; Habashneh, AY; Taha, MO1

Other Studies

5 other study(ies) available for aspartic acid and imatinib mesylate

ArticleYear
Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells.
    Oncogene, 1999, Feb-11, Volume: 18, Issue:6

    Topics: Apoptosis; Aspartic Acid; Benzamides; Calcium-Calmodulin-Dependent Protein Kinases; Caspase Inhibitors; Caspases; Enzyme Activation; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid; Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; U937 Cells

1999
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
    The Journal of biological chemistry, 2004, Jul-23, Volume: 279, Issue:30

    Topics: Amino Acid Motifs; Amino Acid Sequence; Aspartic Acid; Benzamides; Catalytic Domain; Conserved Sequence; Crystallography, X-Ray; Enzyme Activation; Enzyme Inhibitors; Humans; Imatinib Mesylate; In Vitro Techniques; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Piperazines; Protein Conformation; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Recombinant Proteins; Sequence Homology, Amino Acid; Static Electricity

2004
FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
    Oncogene, 2006, Jan-05, Volume: 25, Issue:1

    Topics: Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammation; Inhibitory Concentration 50; Macrophage Colony-Stimulating Factor; Mice; Mutation; Neoplasms; Oncogene Protein v-cbl; Phosphorylation; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-crk; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, Macrophage Colony-Stimulating Factor; Signal Transduction; Time Factors; Valine

2006
Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:4

    Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histidine; Humans; Imatinib Mesylate; Mice; Mice, Nude; Mutation, Missense; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Xenograft Model Antitumor Assays

2013
Synthesis and Structure-Activity Relationship; Exploration of some Potent Anti-Cancer Phenyl Amidrazone Derivatives.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2018, Volume: 14, Issue:5

    Topics: Antineoplastic Agents; Aspartic Acid; Cell Line, Tumor; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Hydrazones; Hydrogen Bonding; Imatinib Mesylate; Ligands; Molecular Docking Simulation; Piperazines; Protein Binding; Structure-Activity Relationship; Threonine

2018